Streamlining Drug Development: From Developability Assessment To High-Concentration Formulation Development
To meet the growing demand for complex and high-concentration biologics, early insight into molecular properties has become essential in formulation development. Samsung Biologics offers a strategic approach combining predictive assessments and formulation optimization platforms. DEVELOPICK™ 3.0 enables early candidate evaluation using small protein quantities and enhanced in silico tools, while S-HiCon™ provides optimized high-concentration formulation conditions through a systematic screening workflow.
Discover how Samsung Biologics leverages these platforms to reduce development risk and accelerate formulation — supporting efficient, high-quality drug product development.
Key learning objectives:
- Learn how DEVELOPICK™ 3.0 enables early risk assessment with minimal protein input and enhanced in silico insights
- Understand how rapid hydrophobicity testing supports proactive formulation and process planning
- Discover how the S-HiCon™ platform helps define optimal conditions for high-concentration formulations over 100 mg/mL
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.